United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,259 shares of the stock in a transaction dated Thursday, May 11th. The stock was sold at an average price of $122.00, for a total transaction of $153,598.00. Following the transaction, the chief executive officer now directly owns 1,399 shares in the company, valued at approximately $170,678. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

United Therapeutics Corporation (UTHR) traded down 0.43% during midday trading on Friday, hitting $129.92. The stock had a trading volume of 578,775 shares. The company has a market cap of $5.85 billion, a PE ratio of 9.12 and a beta of 1.56. The stock’s 50 day moving average price is $124.34 and its 200-day moving average price is $138.37. United Therapeutics Corporation has a 52 week low of $97.52 and a 52 week high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, April 26th. The biotechnology company reported $3.89 EPS for the quarter, beating the Zacks’ consensus estimate of $3.12 by $0.77. The firm had revenue of $370.50 million for the quarter, compared to analyst estimates of $399.59 million. United Therapeutics Corporation had a net margin of 41.04% and a return on equity of 34.74%. The company’s revenue for the quarter was up .4% compared to the same quarter last year. During the same period in the previous year, the business earned $3.02 earnings per share. Equities research analysts predict that United Therapeutics Corporation will post $14.42 earnings per share for the current year.

Insider Buying and Selling by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

TRADEMARK VIOLATION NOTICE: “United Therapeutics Corporation (UTHR) CEO Sells $153,598.00 in Stock” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/06/16/united-therapeutics-co-uthr-ceo-martine-a-rothblatt-sells-1259-shares-updated-updated-updated.html.

Several brokerages have recently commented on UTHR. Jefferies Group LLC reaffirmed a “sell” rating and set a $105.00 price target on shares of United Therapeutics Corporation in a research report on Thursday, June 8th. ValuEngine cut shares of United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 2nd. BidaskClub raised shares of United Therapeutics Corporation from a “strong sell” rating to a “sell” rating in a research report on Friday, June 9th. Zacks Investment Research cut shares of United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research report on Monday, February 27th. Finally, Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of United Therapeutics Corporation in a report on Monday, April 3rd. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $137.09.

A number of institutional investors have recently added to or reduced their stakes in the stock. Skandinaviska Enskilda Banken AB publ raised its position in United Therapeutics Corporation by 1.1% in the first quarter. Skandinaviska Enskilda Banken AB publ now owns 661,723 shares of the biotechnology company’s stock worth $89,584,000 after buying an additional 6,900 shares during the period. Public Employees Retirement System of Ohio raised its position in United Therapeutics Corporation by 0.7% in the first quarter. Public Employees Retirement System of Ohio now owns 20,886 shares of the biotechnology company’s stock worth $2,828,000 after buying an additional 155 shares during the period. Achmea Investment Management B.V. purchased a new position in United Therapeutics Corporation during the first quarter worth approximately $2,297,000. Janus Capital Management LLC raised its position in United Therapeutics Corporation by 122.1% in the first quarter. Janus Capital Management LLC now owns 14,305 shares of the biotechnology company’s stock worth $1,936,000 after buying an additional 7,863 shares during the period. Finally, HighTower Advisors LLC raised its position in United Therapeutics Corporation by 2.1% in the first quarter. HighTower Advisors LLC now owns 36,179 shares of the biotechnology company’s stock worth $4,869,000 after buying an additional 743 shares during the period.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.